Cited by 126Influenza Virus Research StudiesRheumatoid Arthritis Research and TherapiesImmunodeficiency and Autoimmune Disorders

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

Open access

Eisenberg, Robert A., Jawad, Abbas F., Boyer, Jean, Maurer, Kelly, McDonald, Kenyetta, Prak, Eline T. Luning, Sullivan, Kathleen E·2013·Journal of Clinical Immunology

DOI 10.1007/s10875-012-9813-xPMC PMC3565069

Open this paper in CoChat — free account

Abstract

The efficacy of influenza vaccination in patients treated with rituximab is a clinically important question. Rheumatology clinics are populated with patients receiving rituximab for a broad array of disorders. Although several studies have explored the efficacy of other vaccines in rituximab-treated populations, results have been conflicting. We wished to define influenza vaccine efficacy in a rituximab-treated cohort. We examined 17 evaluable subjects treated with rituximab for rheumatologic conditions. T cell subsets, B cells subsets, T cell function, and B cell function were evaluated at specific time points along with hemagglutinination inhibition titers after receiving the standard inactivated influenza vaccine. T cell subset counts were significantly different than controls but did not change with rituximab. B cells depleted in all patients but were in various stages of recovery at the time of vaccination. Influenza vaccine responsiveness was poor overall, with only 16 % of subjects having a four-fold increase in titer. Pre-existing titers were retained throughout the study, however. The ability to respond to the influenza vaccine appeared to be related to the degree of B cell recovery at the time of vaccination. This study emphasizes that antibody responses to vaccine are impaired in subjects treated with rituximab and supports the concept that B cell recovery influences influenza vaccine responsiveness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s10875-012-9813-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I. E., Matteson, E. L., & Montori, V. M. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,470
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 1,964
Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009
Jain, S., Kamimoto, L., Bramley, A. M., Schmitz, A. M., Benoit, S. R., Louie, J., Sugerman, D. E., Druckenmiller, J. K., Ritger, K. A., Chugh, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906695 · Cited by 1,700
Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study
Doran, M. F., Crowson, C. S., Pond, G. R., O’Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10524 · Cited by 1,213
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D. E., Pirani, A. M., Gernert, K. M., Deng, J., Marzolf, B., et al. (2008) · Nature Immunology · doi:10.1038/ni.1688 · Cited by 1,123
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in Children
Neuzil, K. M., Mellen, B. G., Wright, P. F., Mitchel, E. F., & Griffin, M. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001273420401 · Cited by 1,099
Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011
(2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03793.x · Cited by 957
The Efficacy of Influenza Vaccination in Elderly Individuals
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 883
T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly
McElhaney, J. E., Xie, D., Hager, W. D., Barry, M. B., Wang, Y., Kleppinger, A., Ewen, C., Kane, K. P., & Bleackley, R. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6333 · Cited by 561
Influenza in Immunosuppressed Populations
Kunisaki, K. M., & Janoff, E. (2009) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(09)70175-6 · Cited by 519
Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459
Effector CD4+ and CD8+ T‐cell mechanisms in the control of respiratory virus infections
Doherty, P. C., Topham, D. J., Tripp, R. A., Cardin, R. D., Brooks, J. W., & Stevenson, P. G. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb01010.x · Cited by 429
Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Aydintug, A., Jędryka-Góral, A., de Ramón, E., Fernández‐Nebro, A., et al. (1999) · Medicine · doi:10.1097/00005792-199905000-00003 · Cited by 429
The burden of influenza illness in children with asthma and other chronic medical conditions
Neuzil, K. M., Wright, P. F., Mitchel, E. F., & Griffin, M. R. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.110445 · Cited by 381
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab
van Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25033 · Cited by 371 · cited 1×
“Some studies have found an association of vaccine responses with the degree of B cell depletion [37, 43, 47] while others have not found such an association [36, 38, 39].”
Background
Haemagglutination-inhibiting antibody to influenza virus.
de Jong, J. C., Palache, A. M., BEYER, W. E. P., Rimmelzwaan, G. F., Boon, A. C. M., & Osterhaus, A. D. M. E. (2003) · PubMed · Cited by 319
The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. L. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 266
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Фомин, И. Н., Caspi, D., Levy, V., Varsano, N., Shalev, Y., Paran, D., Levartovsky, D., Litinsky, I., Kaufman, I., Wigler, I., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.036434 · Cited by 266
Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children
Forrest, B. D., Pride, M. W., Dunning, A. J., Capeding, M. R., Chotpitayasunondh, T., Tam, J. S. L., Rappaport, R., Eldridge, J. H., & Gruber, W. C. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00397-07 · Cited by 260
Mortality due to Influenza in the United States—An Annualized Regression Approach Using Multiple-Cause Mortality Data
Dushoff, J. G., Plotkin, J. B., Viboud, C. G., Earn, D. J. D., & Simonsen, L. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwj024 · Cited by 257
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
Oren, S., Mandelboim, M., Braun‐Moscovici, Y., Paran, D., Ablin, J. N., Litinsky, I., Comaneshter, D. S., Levartovsky, D., Mendelson, E., Azar, R., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077461 · Cited by 242
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice
Kreijtz, J. H. C. M., Bodewes, R., van Amerongen, G., Kuiken, T., Fouchier, R. A. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.036 · Cited by 229
Influenza-Associated Morbidity and Mortality in Young and Middle-Aged Women
Neuzil, K. M., Reed, G. W., Mitchel, E. F., & Griffin, M. R. (1999) · JAMA · doi:10.1001/jama.281.10.901 · Cited by 222
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S. L., Tsai, D., Pullman‐Mooar, S., Barnack, F., Striebich, C. C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
Self-citation
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., Johnston, L., Wong, R. M., Shizuru, J. A., & Horning, S. J. (2003) · Blood · doi:10.1182/blood-2003-04-1257 · Cited by 200
Community Respiratory Virus Infections in Immunocompromised Patients: Hematopoietic Stem Cell and Solid Organ Transplant Recipients, and Individuals with Human Immunodeficiency Virus Infection
Kim, Y., Boeckh, M., & Englund, J. A. (2007) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-976494 · Cited by 196
Host Defenses Against Influenza Virus: The Role of Anti-Hemagglutinin Antibody
Virelizier, J. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.2.434 · Cited by 184
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?
BEYER, W. E. P., Palache, A. M., Lüchters, G., Nauta, J. J. P., & Osterhaus, A. D. M. E. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.024 · Cited by 179
Mortality in systemic vasculitis: a systematic review.
Phillip, R., & Luqmani, R. A. (2008) · PubMed · Cited by 179
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Yri, O. E., Torfoss, D., Hungnes, O., Tierens, A. M., Waalen, K., Nordøy, T., Dudman, S. G., Kilander, A., Wader, K. F., Østenstad, B., et al. (2011) · Blood · doi:10.1182/blood-2011-08-372649 · Cited by 168
Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis
Fessler, B. J. (2002) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0226 · Cited by 155
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study
Gabay, C., Bel, M., Combescure, C., Ribi, C., Meier, S., Posfay-Barbe, K. M., Grillet, S., Seebach, J. D., Kaiser, L., Wunderli, W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30325 · Cited by 140
Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritisSafety and immunogenicity
Porto, F. D., LAGANA, B., Biselli, R., Donatelli, I., Campitelli, L., Nisini, R., Cardelli, P., Rossi, F. M., & D’Amelio, R. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.028 · Cited by 138
Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or γδ T Cells
Benton, K. A., Misplon, J. A., Lo, C.-Y., Brutkiewicz, R. R., Prasad, S. A., & Epstein, S. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7437 · Cited by 132
The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab
Arad, U., Tzadok, S., Amir, S., Mandelboim, M., Mendelson, E., Wigler, I., Sarbagil‐Maman, H., Paran, D., Caspi, D., & Elkayam, O. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.072 · Cited by 132
Priming with Cold-Adapted Influenza A Does Not Prevent Infection but Elicits Long-Lived Protection against Supralethal Challenge with Heterosubtypic Virus
Powell, T. J., Strutt, T. M., Reome, J. B., Hollenbaugh, J. A., Roberts, A. D., Woodland, D. L., Swain, S. L., & Dutton, R. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.1030 · Cited by 130
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination
Zangwill, K. M., & Belshe, R. B. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000116292.46143.d6 · Cited by 119
Effect of rituximab on human in vivo antibody immune responses
Pescovitz, M. D., Torgerson, T. R., Ochs, H. D., Ocheltree, E., McGee, P., Krause-Steinrauf, H. J., Lachin, J. M., Canniff, J. D., Greenbaum, C. J., Herold, K. C., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.08.008 · Cited by 113
Seasonal inactivated influenza virus vaccines
Couch, R. B. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.076 · Cited by 107
Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens
Bedognetti, D., Zoppoli, G. M., Massucco, C., Zanardi, E., Zupo, S., Bruzzone, A., Sertoli, M. R., Balleari, E., Racchi, O., Messina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004095 · Cited by 106
Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children
Levin, M. J., Song, L., Fenton, T., Nachman, S., Patterson, J., WALKER, R. E., Kemble, G. W., Allende, M. C., Hultquist, M., Yi, T., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.054 · Cited by 94
B Cells Promote Resistance to Heterosubtypic Strains of Influenza via Multiple Mechanisms
Rangel‐Moreno, J., Carragher, D. M., Misra, R. S., Kusser, K. L., Hartson, L., Moquin, A., Lund, F. E., & Randall, T. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.454 · Cited by 91
THE ONCOGENICITY OF CHLORAMBUCIL IN RHEUMATOID ARTHRITIS
Patapanian, H., GRAHAM, S., Sambrook, P. N., Browne, C. D., Champion, G. D., COHEN, M. L., & Day, R. O. (1988) · Lara D. Veeken · doi:10.1093/rheumatology/27.1.44 · Cited by 91
Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases
Elkayam, O., Sharon, A., Mendelson, E., Schwaber, M. J., Grotto, I., Wollman, J., Arad, U., Brill, A., Paran, D., Levartovsky, D., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20465 · Cited by 91
Inactivated Influenza Virus Vaccines in Children
Ruben, F. L. (2004) · Clinical Infectious Diseases · doi:10.1086/382883 · Cited by 84
Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features
Crowe, S. R., Merrill, J. T., Vista, E. S., Dedeke, A. B., Thompson, D. M., Stewart, S. A., Guthridge, J. M., Niewold, T. B., Franek, B. S., Air, G. M., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30388 · Cited by 77
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults
Keitel, W., Couch, R. B., Cate, T. R., Hess, K. R., Baxter, B. D., Quarles, J. M., Atmar, R. L., & Six, H. R. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.10.2468-2473.1994 · Cited by 74
Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents With Advanced HIV Infection
Neuzil, K. M., Coffey, C. S., Mitchel, E. F., & Griffin, M. R. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200311010-00008 · Cited by 69
A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery
Sutter, J. A., Kwan‐Morley, J., Dunham, J., Du, Y., Kamoun, M., Albert, D., Eisenberg, R. A., & Prak, E. T. L. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.012 · Cited by 62
Self-citation
Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice.
Kris, R., Yetter, R. A., Cogliano, R. C., Ramphal, R., & Small, P. A. (1988) · PubMed Central · Cited by 57
Mortality in rheumatoid arthritis.
Symmons, D. P. M. (1988) · PubMed · Cited by 54
Impact of influenza vaccination on mortality risk among the elderly
Groenwold, R. H. H., Hoes, A. W., & Hak, E. (2009) · European Respiratory Journal · doi:10.1183/09031936.00190008 · Cited by 53
A Prospective Study of Influenza Vaccination and a Comparison of Immunologic Parameters in Children and Adults with Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)
Jawad, A. F., Prak, E. T. L., Boyer, J., McDonald‐McGinn, D. M., Zackai, E. H., McDonald, K. R., & Sullivan, K. E. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9569-8 · Cited by 42
Self-citation
Monoclonal antibodies detect different forms of influenza virus hemagglutinin during viral penetration and biosynthesis
Bächi, T., Gerhard, W., & Yewdell, J. W. (1985) · Journal of Virology · doi:10.1128/jvi.55.2.307-313.1985 · Cited by 36
Breakdown of the blood-cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus
Doherty, P. C., & Gerhard, W. (1981) · Journal of Neuroimmunology · doi:10.1016/0165-5728(81)90027-8 · Cited by 35
INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS
Malhotra, A., & Krilov, L. R. (2000) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70211-x · Cited by 31
The Efficacy of Influenza Vaccination in a Pediatric Oncology Population
Reilly, A. F., Kersun, L. S., McDonald, K. R., Weinberg, A., Jawad, A. F., & Sullivan, K. E. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181d869f3 · Cited by 24
Self-citation
Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells
Stevenson, P. G., Hawke, S., & Bangham, C. R. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.3065 · Cited by 22
Protection against Influenza Virus Encephalitis by Adoptive Lymphocyte Transfer
Stevenson, P. G., Hawke, S., & Bangham, C. R. M. (1997) · Virology · doi:10.1006/viro.1997.8535 · Cited by 15

Sorted by citations

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Furer, V., Rondaan, C., Heijstek, M. W., Agmon‐Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D’Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 859
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., Zisapel, M., Elalouf, O., Kaufman, I., Meidan, R., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220647 · Cited by 654
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 506
Self-citation
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis
Bar‐Or, A., Calkwood, J., Chognot, C., Evershed, J., Fox, E., Herman, A. E., Manfrini, M., McNamara, J., Robertson, D. S., Stokmaier, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010380 · Cited by 339
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Bhoj, V. G., Arhontoulis, D. C., Wertheim, G. B. W., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694356 · Cited by 282

See all 126

Authors: Eisenberg, R. A., Jawad, A. F., Boyer, J., Maurer, K., McDonald, K., Prak, E. T. L., & Sullivan, K. E.
Affiliations: University of Pennsylvania (US)
Children's Hospital of Philadelphia (US)
Abramson Cancer Center (US)
Corresponding author: Sullivan, Kathleen E
ORCID: Boyer, Jean
Maurer, Kelly
Prak, Eline T. Luning
Sullivan, Kathleen E
Venue: Journal of Clinical Immunology
Publisher: Springer Science and Business Media LLC
Published: 2012-10-14
Volume: 33
Issue: 2
Pages: 388-396
ISSN: 0271-9142 (ISSN-L)
1573-2592
DOI: 10.1007/s10875-012-9813-x
PMC: PMC3565069
OpenAlex: W1977749342
Cited by: 126
References: 63
Citations by year: 2026: 3 · 2025: 8 · 2024: 3 · 2023: 11 · 2022: 20 · 2021: 31 · 2020: 8 · 2019: 3 · 2018: 3 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 7 · 2013: 7
FWCI: 4.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Clinical Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (n01ai50024-7-0-1)
National Cancer Institute (P30CA016520)
National Institute of Allergy and Infectious Diseases (N01-AI-50024, R01AI063626, N01 AI050024)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR034156)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords: rituximab, influenza vaccination, vaccine response, B-cell depletion, B cell recovery, T cell subsets, humoral immunity, rheumatic diseases, hemagglutination inhibition, antibody response
MeSH terms: Rituximab, Adult, Aged, Antibodies, Viral, B-Lymphocytes, Female, Humans, Immunoglobulin G, Immunologic Memory, Influenza, Human, Influenza Vaccines, Lymphocyte Depletion, Male, Middle Aged, Rheumatic Diseases, T-Lymphocyte Subsets, Antirheumatic Agents, Lymphocyte Count, Antigens, CD19, Immunity, Humoral, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks